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signals from a pulsed proton beam (about 5 pC/pulse, 6 µs 
FWHM) and detector shifts down to 2 mm. The measured 
relative shifts of the Bragg peak position of 2.3 mm for 1 MeV 
energy change and 173.25 mm for 82 MeV are in perfect 
agreement with Geant4 predictions. However, the low signal 
amplitude below 1 mV required an averaging with 1024 
acquisitions. 
Conclusion: Measuring the ionoacoustic signal at the IBA 
synchro-cyclotron, the detectability of 2 mm range shifts 
could be demonstrated. Experimental upgrades will be 
discussed, from which we reasonably assume to improve the 
resolution to 1 mm and below. In order to determine an 
absolute ion range in water in future ionoacoustic 
experiments, a method using an additional ultrasound 
transducer to measure the distance of the hydrophone to the 
water surface was developed. Remaining challenges on signal 
detectability for clinical dose rates as well as perspectives of 
future setup improvements will be discussed. 
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Purpose: Online in vivo control of the ion range in a patient 
during proton therapy is a major challenge for quality 
assurance of treatments. After measurements showed that 
prompt-γ emission is correlated to the ion range (Min et al 
2006, Testa et al 2008), prompt-γ imaging emerged as a 
promising method (Verburg et al 2013). Fast methods are 
required to compute accurate prompt-γ emission maps to 
design and predict the camera response from treatment 
plans. An analytic computation method based on the 
structure of the dose calculation engines in treatment 
planning system has recently been proposed (Sterpin et al 
2015). An alternative technique based on variance reduction 
in Monte Carlo (MC) calculations is developed here for 
computing prompt-γ emission maps in proton therapy.  
Materials/Methods: The track length estimator (TLE) method 
is a standard variance reduction technique in voxel-based 
dose computation in the kerma approximation (Williamson 
1987), and similar approaches have also been developed for 
positron emitter distributions in proton therapy (Parodi et al 
2007). A specific track length estimator has been developed 
here to design a continuous process along the proton track 
that locally deposits the expected value of the prompt-γ 
emission (induced by proton inelastic scattering) that would 
have occurred if a large number of protons with the same 
incident energy had followed the same step (i.e. track 
element). First an elemental database of prompt-γ emission 
spectra is established in the clinical energy range of incident 
protons for all elements in the composition of human tissues. 
This database of the prompt-γ spectra is built offline with 
high statistics. Regarding the implementation of the prompt-
γ TLE MC tally, each proton deposits along its track the 
expectation of the prompt-γ spectra from the database 
according to the proton kinetic energy and the local material 
density and composition. All software developments have 
been carried out with the Gate/Geant4 toolkit. 
Results: A detailed statistical analysis is reported to 
characterize the dependency of the variance reduction on 
the geometrical (track length distribution) and physical 
(linear prompt-γ spectrum database) parameters. 
Benchmarking of the proposed technique with respect to an 
analogous MC technique is carried out. A large relative 
efficiency gain is reported, ca. 105. Such an efficiency gain 
could reduce the MC computing time of a full treatment from 
some weeks to less than one hour. Implementation issues are 
also addressed. 
Conclusions: This MC-based technique makes it possible to 
deal with complex situations such as heterogeneities for 
which proton straggling and secondary protons may have a 
decisive contribution. When considering translation to clinic, 
measurements for the prompt-γ spectrum database, or at 
least a sound calibration protocol of the simulated prompt-γ 
spectra, will have to be carried out. 
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Since the gastrin-releasing peptide receptor(GRPR) has been 
shown to be overexpressed in prostate cancer, bombesin 
which is the ligand of GRPR has been investigated to be a 
successful candidate for the peptide receptor 
radiotherapy(PRRT)[1]. The present study describes the 
imaging and therapeutic efficacy of the theranostic 
twins(68Ga/177Lu)-labeled bombesin derivatives for the PRRT 
of GRPR-overexpressing prostate tumors. 
A series of DOTA-conjugated bombesin derivatives were 
synthesized using a solid-phase synthesis. Competitive 
binding studies were performed for selecting a GRPR-
targeting peptide with high affinity. The selected peptide 
was labeled with 68Ga using the NaCl method for imaging[2], 
and labeled with 177Lu which was produced by the HANARO 
research reactor (thermal neutron flux of 1.8 × 1014 n·cm-2·s-
1) for therapy. The labeling yield was evaluated by iTLC-SG, 
and the PET/CT imaging and therapeutic efficacy of the 
radiolabeled peptides were evaluated using nude mice 
bearing PC-3 human prostate carcinoma xenograft. 
Hydrophilic-modified bombesin derivative showed a 
nanomolar binding affinity for GRPR. The peptide was labeled 
with the both radionuclides in high incorporation 
yields(>98%). 68Ga-labeled peptide was quickly cleared from 
the blood and clearly visualized in PC-3 tumors at 1 hr p.i. 
177Lu-labeled peptide were also rapidly accumulated in a PC-3 
tumor, and the % ID/g of the tumor was 12.42 ± 2.15 1 hr p.i. 
The radio-peptide significantly inhibited the tumor growth 
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(P<0.05), and treatment-related toxicity was not observed in 
the pancreas and kidneys while slight glomerulopathy was 
detected. 
The pharmacokinetic, imaging, and therapy studies suggest 
that the theranostic twins(68Ga/177Lu)-labeled bombesin 
derivatives have promising characteristics for application in 
nuclear medicine, namely, for the diagnosis and treatment of 
GRPR-overexpressing prostate tumors. 
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Hypothesis: Radiation fibrosis (RF) effects up to 70% of 
patients who have undergone radiotherapy.  It is 
characterized by irreversible scarring of normal tissue 
resulting in functional morbidity and increased risk of 
surgical complications. Adipose-derived stromal cells (ADSCs) 
are a subcategory of mesenchymal stromal cell. Much of the 
therapeutic benefit of ADSCs has been attributed to secretion 
of cytokines and growth factors involved in 
immunomodulation, cell survival, and metabolism. We 
hypothesize that ADSCs may be therapeutically effective for 
RF through reversal of metabolic aberrations. 
Methods: A mouse model of RF was developed and ADSC 
isolation was confirmed by surface marker expression and by 
differentiation capacity down the mesenchymal lineage. GFP 
and luciferase labelled ADSCs were used to assess 
biodistribution and cell survival after transplantation. To 
determine the therapeutic effect of ADSC transplantation for 
RF, we assessed functional changes to tissue elasticity using a 
leg contracture measurement tool and to collagen deposition 
using trichrome blue staining. To determine the mechanism 
of ADSC-mediated fibrosis reversal, we assessed 
transcriptomic changes to RF tissue.  
Results: A RF model was created by radiating the hind limb of 
C3H mice. This model showed a dose dependent leg 
contracture and histological findings of fibrosis. We 
confirmed the immunophenotype of isolated ADSC and their 
ability to differentiate into adipogenic, chondrogenic, and 
osteogenic lineages. ADSC transplantation showed a 
statistically significant trend towards improved leg 
contracture (2-way ANOVA, p<0.05) and reduced collagen 
deposition. Biodistribution studies confirmed the presence of 
ADSCs in the subdermis of RF tissue with persistence for at 
least 18 days post-transplantation.  Preliminary RNA-seq 
over-representation pathway analysis showed that lipid 
metabolism and PPARG signaling were among the top 
pathways down regulated in radiation fibrosis and was 
partially reversed with ADSC treatment. ADSCs directly 
reversed alterations to lipid metabolism in radiated 
fibroblasts through indirect co-culture.  
Conclusions: ADSC transplantation may be an effective 
treatment for the reversal of radiation fibrosis through 
metabolic reprogramming. As cancer survivorship increases, 
the prevalence of radiation fibrosis will rise and necessitate 
increased focus on effective treatment strategies for this 
condition.   
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Purpose: The detection of gamma rays for monitoring 
purposes can overcome some of the limitations of PET, since 
they are more abundant than positron emitters and are 
produced within nanoseconds after irradiations. However, 
their continuous emission spectrum up to high energies (more 
than 10 MeV) make their detection challenging [1]. 
Collimated systems and Compton cameras are being 
developed for this application. 
The IRIS group of the Instituto de Fisica Corpuscular (IFIC-
CSIC/UVEG, Valencia) has developed a three-layer Compton 
telescope based on LaBr3 scintillator crystals for hadron 
therapy monitoring within the ENVISION project.   
Materials and Methods: The telescope consists of three planes 
of LaBr3 crystals, which provide high energy resolution and 
fast response, coupled to silicon photomultiplier arrays. A 
custom made data acquisition system has been developed to 
read out the detectors and operate them in time 
coincidence, employing the VATA64HDR16 ASIC[2]. The 
system aims at combining two- and three-layer events in 
order to profit from the high efficiency of the former and the 
high precision of the latter. The functionality of the device 
has been tested in the laboratory with radioactive sources, 
and also in beam tests. A dedicated image reconstruction ML-
EM code has also been developed for both types of events. 
Results: The system has been characterized in the laboratory 
acquiring data with radioactive sources of different energies. 
The detector response in terms of linearity, uniformity and 
spatial, energy and timing resolution has been obtained for 
the three layers, improving the results of the first tests. In 
addition, images of a point-like Na-22 source have been 
reconstructed with two and three-layer systems. The 
preliminary spatial resolution obtained is 7.3 mm FWHM with 
the two-layer system and 8.6 mm FWHM with the three-layer 
system.  
The two-layer system has also been tested in a proton beam 
at KVI-CART, Groningen. Data were taken with a 150 MeV 
proton beam with an intensity of about 108 protons/s and a 
lateral beam spread of 5.3 mm impinging on a PMMA 
phantom. The PMMA target was placed in two different 
positions along the beam separated by 10 mm. The data 
analysis and image reconstruction of the data have shown a 
difference in the reconstructed profile consistent with the 
phantom position [3]. 
Conclusions: The laboratory tests carried out assess the 
correct functioning of the device. In-beam results show the 
capability of detecting range shifts. Current work is focused 
on performance improvement of the system and on 
simultaneous operation of two and three detector layers. 
Further tests in beam are planned at HZDR Dresden for 
December 2015. 
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